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ABSTRACT
Genome-wide association studies (GWAS) and follow-up studies in celiac dis-
ease (CeD) have identified 39 loci, besides HLA, associated with this disease. 
Together they explain approximately 54% of the total genetic risk of the CeD 
phenotype. More of the heritable component might be hidden between the as-
sociation signals that did not meet the stringent statistical thresholds imposed 
after correction for multiple testing. 
To obtain a proof-of-principle for the presence of such hidden disease-associat-
ed loci, we selected six single nucleotide polymorphisms (SNPs) with suggestive 
association signals that did not meet the genome-wide significance statistics we 
had set for follow-up. These six SNPs were genotyped by TaqMan and tested 
for association with CeD in two independent cohorts of Dutch (180 CeD cases, 
511 controls) and Italian (824 CeD cases, 1,304 controls) ancestry. The results 
were combined with those from our original GWAS discovery cohort of 3,796 
CeD cases and 8,154 controls from four populations (British, Finnish, Dutch 
and Italian). The combined meta-analysis revealed two potential novel CeD 
genetic variants: rs12086216 on chromosome 1 (P=1.45x10-6) and rs12700692 
on chromosome 7 (P=1.1x10-6). We correlated the genotypes of these two SNPs 
with the levels of gene expression in whole blood samples of 629 Dutch indi-
viduals. We discovered a cis-eQTL effect of the SNP on chromosome 7 on the 
expression of the protein-coding gene NFE2L3 (the T allele lowered the expres-
sion of NFE2L3). Consequently we investigated the NFE2L3 gene expression 
using RNA from various immune cell types obtained from whole blood and 
from intestinal biopsies representing CeD-relevant cell types and tissues. The 
highest expression of NFE2L3 was observed in monocytes, followed by memo-
ry T-cells, albeit the latter showed only half the expression. Analysis of publicly 
available expression data revealed higher levels of NFE2L3 in LPS-stimulated 
monocytes than in unstimulated monocytes or CD4+ T-cells. Analysis of CeD-
relevant tissues from intestinal biopsies showed a significant relation between 
disease severity/classification and increased levels of NFE2L3. 
We have identified NFE2L3 as a potential novel risk gene for CeD. Our results 
show that our approach (increasing the sample size, combined with follow-up 
studies) can successfully provide evidence for potential risk genes.
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INTRODUCTION
Celiac disease (CeD) is a common immune- 
related disorder characterized by intolerance to 
dietary gluten resulting in a chronic inflamma-
tion in the small intestine of susceptible indi-
viduals. Linkage analysis and association-based 
studies have established the role of genetics in 
CeD. The strongest genetic components are 
found in the human leukocyte antigen (HLA) 
class II genes in the major histocompatibility 
complex (MHC) on chromosome 6. 
Genome-wide association studies (GWAS) 
and Immunochip analysis in CeD have 
successfully identified 39 non-HLA loci 
associated to this disease [1–4]. The great 
majority (~95%) of the CeD-associated 
SNPs (single nucleotide polymorphisms) 
are located in non-protein-coding regions 
[5]. This is consistent with GWAS findings 
in general, where more than 1,200 GWAS 
for diverse diseases and quantitative traits 
have together shown that ~93% of the as-
sociated SNPs reside in non-coding regions. 
This observation makes it challenging to 
translate associated SNPs to function [6, 7]. 
Correlating the messenger RNA (mRNA) 
gene expression levels with SNPs and iden-
tifying expression-quantitative trait loci 
(eQTL) may help to functionally annotate 
GWAS SNPs and identify which genes are 
likely to be regulated by specific SNP vari-
ants [8]. The eQTLs may map close to genes 
(cis-eQTL) or much further away, or even 
on different chromosomes (trans-eQTL). 
Several publications have suggested that 
disease-associated variants are involved in 
regulating the transcription of specific tar-
get genes via interaction with promoters or 
enhancers, by altering/creating transcription 
factor binding sites, or removing chroma-
tin-modifying complexes to open the chro-
matin to make it more accessible [9–12]. 
Maurano et al. showed that the majority of 
GWAS-variants associated with diseases or 
quantitative traits are concentrated in regu-
latory parts of DNA in a cell-specific and/or 
developmental-stage manner [7]. This sug-
gests that CeD-associated variants captured 
by GWAS but not located in the protein-cod-
ing DNA could cause the disease phenotype 
via non-coding genes or non-coding regula-
tory elements (promoters, enhancers, tran-
scription factor binding sites) close by or at 
a distance. This type of regulation should be 
selective and cell-type- or tissue-specific. 
We hypothesized that CeD-associated 
SNPs can affect the expression of coding or 
non-coding genes previously not known to 
have an immune-related function. To test 
this hypothesis, we selected SNPs previously 
associated with CeD in GWAS [3] but which 
were not located close to known immune-re-
lated protein-coding genes and hence not in-
cluded in follow-up replication studies. They 
were, however, located in a region of long 
non-coding RNA (lncRNA) genes. We hy-
pothesized that these SNPs may cluster with 
perfect proxies in regulatory elements in the 
disease-relevant cell type (immune cell types 
or intestinal epithelial cells) and thus affect 
the level of transcription of specific coding or 
non-coding target genes in their close prox-
imity or at a distance (cis- or trans-eQTL). 
MATERIAL & METHODS
Subjects
DNA samples were isolated from the whole 
blood of 1,004 celiac disease patients and 
1,815 healthy controls from our Dutch and 
Italian cohorts. All subjects were of European 
ancestry (see Table 1). Written informed 
consent was obtained from all subjects after 
we obtained approval from the ethics com-
mittee or institutional review board of all the 
participating institutes. 
SNP selection
We used the same selection criteria as Dubois 
et al. [3] based on P-values in GWAS (PGWAS <10-4). 
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Table 1: Individuals included in discovery and replication studies






UK, FIN, NL, IT Dutch Italian  
Celiac disease cases 3,796 180 824 4,800
Male/Female/Unspecified 983/2,813/0 48/132/0 284/533/7  
Controls 8,154 511 1,304 9,969
Male/Female/Unspecified 4,261/3,893/0 255/266/0 281/953/70  
Total 11,950 691 2,128 14,769
We selected the six most associated SNPs that 
met the following criteria: (1) these SNPs 
were not included in our previous replica-
tion study because there were no immune 
system protein-coding genes in the region, 
(2) and the SNPs were located in a 500 kb 
window with long non-coding RNA genes 
from the Gencode dataset [13] or Human 
lincRNA catalog [14].
SNP genotyping 
Both the replication cohorts from the 
Netherlands and Italy were directly gen-
otyped at the University Medical Center 
Groningen (Groningen, the Netherlands) 
using TaqMan SNP Genotyping Assays on 
an ABI 7900HT system (Applied Biosystems, 
Bleiswijk, the Netherlands), following the 
manufacturer’s protocol. Genotyping data 
and clustering was performed using SDS 2.3 
software (Applied Biosystems). Genotype 
clusters per SNP were manually investigat-
ed and adjusted if necessary. DNA samples 
were processed in 384-well plates. To control 
for plate swaps, all plates included four geno-
typing control DNA samples (obtained from 
Centre d’Etude du Polymorphisme Humain 
(CEPH) Paris, France) and four negative 
controls (water) per SNP in plate-specific po-
sitions. Additional Dutch controls for replica-
tion cohort 1 (R1) were genotyped using the 
Illumina HiSeq 2000 platform (Illumina Inc., 
San Diego, CA, USA) at the Beijing Genomics 
Institute, China (BGI). The genotype calling 
algorithms and quality control parameters we 
used have been described previously [15]. 
SNP association analysis
SNP association analysis were performed 
using PLINK v1.07 [16]. Standard case-con-
trol association analyses were performed 
using Fisher’s exact test independently for 
each study (R1 and R2). Cochran-Mantel-
Haenszel (CMH) meta-analysis of the odds 
ratio was used in a combined analysis of rep-
lication samples (GWAS+R1+R2). Regional 
linkage disequilibrium (LD) plots were gen-
erated with SNAP software using the 1000 
Genomes project SNP dataset and CEU pop-
ulation for calculating r2 and recombination 
rate visualization [17]. 
Expression quantitative trait loci 
analysis in peripheral blood 
mononuclear cells in a Dutch cohort
We performed a whole-genome eQTL-anal-
ysis using peripheral blood samples and 
genotype data from 629 unrelated Dutch in-
dividuals of the LifeLines Deep cohort [18]. 
We isolated DNA according to standard pro-
tocols and genotyped these samples with the 
Immunochip platform (Human Immuno Bead 
Chip B) and with the HumanCytoSNP-12 
Bead Chip according to the manufacturer’s 
protocol (both platforms from Illumina Inc.). 
The genotypes from both platforms were 
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merged into one dataset. Gene expression 
data for the whole dataset was obtained by 
isolating RNA using PAXgene Blood miRNA 
Kit (Qiagen, CA, USA). We determined RNA 
quantity and quality using the Nanodrop 
1000 Spectrophotometer (Thermo Scientific, 
Waltham, MA, USA) and the Expirion 
high-sensitivity RNA analysis kit (Bio-Rad, 
Hercules, CA, USA), respectively. The RNA 
was concentrated by precipitation and then 
re-diluted in a smaller volume. The sequenc-
ing libraries were prepared using the TruSeq 
version 2 RNA kit (Illumina Inc.) according to 
the manufacturer’s instructions. Ten samples 
per lane were pooled and pair-end sequenced 
of 2 x 50 bp in a single lane on the HiSeq2000 
(Illumina Inc.). RNA sequencing data were an-
alyzed as previously described [18]. 
Sequencing reads were mapped to the 
human reference genome (NCBI build 37) 
using RNA-seq aligner STAR version 2.1.3 
[19]. RNA deep sequencing data were an-
notated with known transcripts from the 
Gencode version 16 dataset (GRCh37.71) 
[13]. Stringent alignment criteria were used 
to ensure that probes mapped unequivocally 
to a single genomic position. The expression 
data were trimmed mean of M-values (TMM) 
normalized [20] and log2-transformed. The 
expression of each gene was centered and 
scaled. Five principal components were in-
cluded as covariates. Both cis- and trans-
eQTL mapping was performed as described 
previously [8]. Genes were included in the cis-
eQTL analysis if their gene expression probes 
were located within a 1 Mb window of the se-
lected SNP (SNP ± 500 kb), whereas eQTLs at 
a distance greater than 5 Mb were defined as 
trans-eQTLs. Associations were corrected for 
multiple comparison/testing using the false 
discovery rate (FDR<0.05).
Functional annotation of replicated 
SNPs
For a replicated SNP (lead SNP) with an eQTL, 
we extracted proxies that were in strong 
linkage disequilibrium (r2≥0.8 or D’=1; 1000 
Genomes project, CEU population as refer-
ence) with the lead SNP using the HaploReG 
v2 tool (http://compbio.mit.edu/ HaploReg), 
[21]. To annotate lead SNPs and their prox-
ies with regulatory elements, we integrated 
ENCODE and Roadmap data, and visualized 
it in the UCSC genome browser (http://ge-
nome.ucsc.edu/) or in the Epigenome browser 
(http://www.epigenomebrowser.org/), [22].
Gene expression analysis in selected 
immune cell types
We performed transcriptome analysis across 
seven peripheral blood leukocyte popula-
tions (granulocytes, monocytes, NK cells, 
B-cells, memory-T cells, naive CD4+ and 
naive CD8+ T-cells) in RNA-sequencing 
data as described previously [23]. We also 
analyzed microarray expression data from 
the Schirmer study [24], which we down-
loaded from the Gene Expression Omnibus 
(GEO) under accession number GSE9820. 
We extracted data from HumanRef-8 v2.0 
expression BeadChip platform (Illumina 
Inc.) for three cell types in controls, resting 
monocytes (n=13), monocytes stimulated by 
LPS (n=13), and T-cells (n=14).
We also performed gene expression anal-
ysis using HumanRef-8 v2.0 microarray data 
derived from disease-relevant tissue which 
was taken from intestinal biopsies of 36 
Dutch individuals (12 controls, 24 CeD pa-
tients classified as Marsh stage 0 (n=12) and 
Marsh 3 (n=12),[25]) as described earlier [2]. 
The normalized expression values were strat-
ified according to the phenotypes (controls 
versus treated CeD (Marsh 0), controls ver-
sus untreated CeD (Marsh 3), treated (Marsh 
0) versus untreated CeD (Marsh 3)), or ac-
cording to the cell type (resting monocytes, 
stimulated monocytes, T-cells); significant 
differences were tested using the Wilcoxon 




Figure 1: Forest plots showing the odds ratios 
and 95% confidence intervals of the association 
for the two replicated SNPs. The dashed line 
represents an odds ratio of 1. 
RESULTS
Six SNPs were selected based on the previ-
ously described parameters (see Materials 
& Methods) and were further directly geno-
typed in two independent cohorts (Table 2), 
from the Netherlands (R1) and Italy (R2), us-
ing TaqMan genotyping assays. Combining 
the results from the discovery GWAS and 
two replication studies into a meta-analysis 
of 14,769 individuals (4,800 CeD cases and 
9,969 healthy controls) revealed two repli-
cated SNPs associated with CeD: rs12086216 
(on chromosome 1) and rs12700692 (on 
chromosome 7) with PMETA=1.45x10-6 (odds 
ratio (OR)=0.757; 95% confidence interval 
(CI), 0.676 to 0.848) and PMETA=1.10x10-6 
(OR=0.852; CI, 0.799 to 0.909), respec-
tively (Table 3, Supp. Table 1, Figure 1). 
Supplementary Table 2 gives detailed infor-
mation about the allele frequencies across 
the different cohorts included in the GWAS, 
both replications studies (R1, R2) and in the 
meta-analysis.
To identify genes which are regulated by 
our two replicated variants, we correlated 
genotypes with the expression in the whole 
blood of 629 controls for genes in a 1 Mb 
locus (cis-eQTL, Figure 2) and for all genes 
located at a distance larger than 5 Mb (trans-
eQTL). No cis-eQTL effect was observed for 
the rs12086216 variant on chromosome 1 
(Supp. Table 3) but we did observe a signifi-
cant cis-eQTL effect (FDR<0.05, P=1.16x10-8) 
on protein-coding gene NFE2L3 for the SNP 
on chromosome 7 (rs12700692), where the 
allele T with protective effect was associat-
ed with a lower expression of the mRNA in 
whole blood (Supp. Table 3, Figure 3). No 
trans-eQTL effect was observed for any of 
the replicated variants (data not shown).
To assess the functional role of the rep-
licated SNP rs12700692 in the associated 
locus on chromosome 7, we investigated the 
regulatory elements and genes (cis-genes) 
in a region defined by proxy SNPs using 
HaploReg, ENCODE and Roadmap data. We 
did not observe any enrichment of regulato-
ry elements in the region on chromosome 7.
To assess the functional role of this 
SNP in disease-relevant cell types, we ana-
lyzed NFE2L3 gene expression in seven im-
mune cell types circulating in the blood of 
healthy individuals using RNA-sequencing 
[27]. The highest expression of NFE2L3 was 
present  in monocytes (24.4 RPKM) followed 
by CD4+/CD8+ memory T-cells (12 RPKM), 
(Figure 4-A). We also compared the expres-




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: NFE2L3 gene expression data in 
disease-relevant cell types and tissue. A) Seven 
immune cell types derived from PBMCs from 
healthy individuals [27]; B)  Schirmer et al. study 
with unstimulated/LPS-stimulated mono-cytes 
and CD4+ T-cells [24]; C)  small intestine tissue 
biopsies obtained from 12 healthy controls, 12 CeD 
patients with a normal histology (M0, Marsh 
stage 0), and 12 untreated CeD patients with 
pathological villous atrophy (M3, Marsh stage 3).
of protein-coding gene NFE2L3 in the 
same region (cis-eQTL), with the lowest 
Figure 3: Expression quantitative trait locus (eQTL) 
mapping for rs12700692 on chromosome 7. 
sion profile of NFE2L3 in publicly available 
microarray expression data (GSE9820) de-
livered from LPS-stimulated and non-stim-
ulated monocytes and using CD4+ T-cells as 
controls [24]. In this dataset, the expression 
of NFE2L3 was highest in LPS-stimulated 
monocytes and lowest in CD4+ T-cells (Figure 
4-B). The difference in NFE2L3 expression 
was significant between all the tested cells 
types (unstimulated vs. stimulated mono-
cytes (P=3.65x10-6), unstimulated monocytes 
vs T-cells (P=1.2x10-6), and stimulated mono-
cytes vs T-cells (P=9.97x10-8)).
Next, to test whether the NFE2L3 gene 
is correlated with the disease phenotype, we 
performed a microarray expression analysis 
on 36 duodenal biopsies from 12 healthy 
controls, 12 treated CeD patients with nor-
mal mucosa/villi architecture (Marsh 0) and 
12 untreated CeD patients with inflamed 
mucosa and villous atrophy (Marsh 3). The 
NFE2L3 gene showed a significant differ-
ence in expression between all three groups 
and was correlated with disease severity: 
the more severe phenotypes had a higher 
expression (Figure 4-C). The difference be-
tween untreated CeD and treated CeD was 
also significant (P=8.9x10-6, Figure 4-C).
This SNP is strongly correlated with expres-
sion levels (P-value of 1.16x10-8, FDR<0.05)
76 CHAPTER 4
level of expression shown by carriers who 
are homozygous for the rs12700692 allele 
T (protective). The SNP-gene expression 
correlation is shown for a dataset containing 
629 individuals from the general population 
(LifeLines Deep cohort). The numbers in 
brackets represent the frequency of specific 
genotypes.
DISCUSSION
Here we describe a replication study of ge-
netic variants with suggested associations to 
CeD seen in GWAS. We identified two novel 
potential risk variants for CeD: rs12086216 
on chromosome 1 and rs12700692 on chro-
mosome 7. The strongest association was 
seen for the variant on chromosome 7 and 
the genotype of this SNP could be correlat-
ed with the expression of the protein-coding 
gene NFE2L3 from the same region. 
CeD is an immune-related, inflamma-
tory disease of the intestine. We therefore 
investigated the expression of NFE2L3 in 
a panel of general, circulating, immune 
cell types, isolated from the whole blood of 
a healthy volunteer and we performed an 
additional analysis of publicly available ex-
pression data [24, 27]. The highest NFE2L3 
expression in monocytes in whole blood 
and the increased levels in monocytes after 
stimulation with LPS that we observed are 
in concordance with the monocyte infiltra-
tion which takes place during active, un-
treated CeD. It has also been observed that 
specific subtypes of monocyte-derived cells 
(CD11+ dendritic cells (DC) co-expressing 
the CD14+ monocyte marker) accumulate 
in the inflamed intestine of untreated CeD 
patients, while the presence of other sub-
sets – dendritic cells and macrophages – is 
decreased [28]. Beitnes et al. [29] studied 
whether this infiltration was caused by the 
inflammation or by the response to the glu-
ten antigen. They observed an increase of the 
subtypes of CD14+CD11c+ DCs after an in 
vivo gluten stimulation, together with a de-
crease of specific CD103+CD11c+ DCs and 
CD163+CD11c- macrophages as observed 
in untreated CeD patients, whereas the con-
trols did not have this reaction [29].
Our analysis of CeD-relevant tissue from 
intestinal biopsies of CeD patients showed 
a correlation of disease severity with higher 
expression levels of NFE2L3. However, the 
difference between treated and untreated 
CeD was not statistically significant, but we 
should take into account that duodenal bi-
opsies are not a single-cell-type tissue, but 
rather a mixture of immune and epithelial 
cells. Therefore, the expression signal from 
one cell type might be diluted by other cell 
types, or even almost silenced by more prev-
alent cell types. This issue could be solved by 
collecting a sufficient amount of duodenal 
tissue so that one could isolate a large num-
ber of different, potentially relevant, cells. At 
present, it is not feasible to dissect the intes-
tinal biopsies to obtain sufficient quantities 
of different cell types for reliable gene ex-
pression data on each type. The invasive na-
ture of an intestinal biopsy makes it difficult 
to collect large samples. This could be solved 
by isolating pure cell types and performing 
single-cell sequencing.
The eQTL analysis disclosed a correlation 
between the rs12700692 (chromosome 7) 
genotype with NFE2L3 expression. To dis-
cover how the associated SNP might regu-
late this protein-coding gene, we annotated 
rs12700692 and its proxy SNPs (r2>0.8) with 
regulatory elements using RegulomeDb [30]. 
The database algorithms predicted a motif 
change (minimal binding evidence, score 
6) for the Sfpi1 transcription factor, but in 
this case the genetic variant was located at 
the end of the recognition sequence, which 
therefore has a very low potential to dis-
rupt the binding of Sfpi1. To validate the 
RegulomeDb prediction, we analyzed pub-
licly available data, using tracks in the UCSC 
genome browser. None of the predicted 
regulatory elements was confirmed in these 
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datasets across different cell types, tissues or 
cell lines. A possible explanation is that there 
is still no regulatory element data available 
for CeD-relevant tissues/cell types or cells 
under a CeD-specific stimulation. The reg-
ulation may be extremely specific and may 
be active in different cell types, such as an-
tigen-presenting cells (monocytes, dendritic 
cells, macrophages) or intestinal epithelial 
cells (enterocytes). RegulomeDb algorithms 
also predicted modification of two histone 
markers H2A.Z (functioning in euchromatin 
to antagonize the spread of heterochroma-
tin) and H3K27me3 (marker of transcrip-
tionally silent chromatin) in several cell lines, 
but again, we did not observe this pattern 
across a large number of different cell types 
or cell lines when we analyzed the data in the 
UCSC genome browser. Performing state-of-
the-art experiments (like chromatin immu-
noprecipitation sequencing (ChIP-seq) or 
global run-on sequencing (GRO-seq)) to re-
veal the regulatory elements in CeD-specific 
cell types in unstimulated and stimulated 
conditions (gluten, cytokines) would help us 
gain an understanding of the precise mecha-
nism of regulation. 
We have identified NFE2L3 (nuclear 
factor (erythroid-derived 2)-like 3) also 
known as NRF3 (NF-E2-related factor 3) as 
a potential risk gene for CeD in this study. 
NFE2L3 glycoprotein was discovered more 
than 10 years ago, but is still a poorly char-
acterized transcription factor and regulator 
of antioxidant-response elements (ARE)-
dependent gene expression [31, 32]. As 
a regulator, NFE2L3 can increase or de-
crease the expression of its target genes, de-
pending on the cellular context, expression 
levels of NFE2L3, and/or its co-factors [33]. 
NFE2L3 has three isoforms that are differ-
ently localized in three subcellular compo-
nents (endoplasmic reticulum, cytoplasm, 
and nucleus) [32, 33]. Results from mouse 
studies suggest a role for NFE2L3 in protec-
tion from hematopoietic malignancies and 
a possible role in inflammation [33, 34]. Few 
studies have reported an increase of NFE2L3 
on the protein and/or transcript level after 
stimulation with pro-inflammatory cyto-
kines TNFα and IFNγ (choriocarcinoma 
cell line JAR, human uterine endothelial 
cells) [35, 36]. A recent study by Fairfax et 
al. [37] investigated regulatory variants in 
monocyte gene expression and reported 
a cis-eQTL effect on the NFE2L3 gene for 
rs2057763 after IFNγ stimulation. Interest-
ingly, this cis-eQTL effect was not observed 
in unstimulated monocytes. All this informa- 
tion is in line with our own findings on 
NFE2L3 and its possible involvement in the 
innate immune system in CeD.
To predict possible pathways for NFE2L3, 
we investigated the NFE2L3 co-expressed 
genes using GeneNetwork to dive deeper 
into the possible CeD mechanism [38]. The 
resulting network included 88 genes. We an-
notated these 88 co-expressed genes with the 
information extracted from ImmunoBase 
database [http://www.immunobase.org], where 
18% (16 out of 88) of the co-expressed genes 
were under a term “disease overlap”, i.e. 
genes associated with at least two out of 12 
autoimmune or immune-related diseases 
(Supp. Table 4, Figure 5), suggesting that 
NFE2L3 might be involved in a mechanism 
shared by various autoimmune and immune- 
related diseases. The co-expression network 
included one well-known CeD-associated 
gene (TNFAIP3) and six other co-ex-
pressed genes linked to the same pathway as 
TNFAIP3, the NFkB pathway (Figure 5). We 
previously implicated this pathway in CeD 
based on GWAS data [4].
One of the most co-expressed genes with 
NFE2L3 in our analysis was Baculoviral IAP 
repeat-containing protein 3 (BIRC3), also 
known as a cellular inhibitor of apoptosis 
protein 2 (cIAP2). This gene has not previ-
ously been linked to any autoimmune or 
immune-related disease. BIRC3 protein is 
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erization domain (NOD)-like receptor sig-
naling via binding to activated NOD1/NOD2, 
which is followed by the RIPK2 activation of 
mitogen-activated protein kinase (MAPK) 
and the NFkB signaling pathway. This re-
sults in the production of pro-inflammatory 
cytokines and chemokines, induction of the 
innate immune system in the intestine, and 
the Th2-type immune response. To date, the 
NOD2 gene and its pathway have been im-
plicated in inflammatory bowel disease, an-
other immune-related disease manifesting 
in the gut [39]. Additionally, there are a few 
studies implicating genetic variants located 
in NLRP1 or NLRP3 (other NOD-like recep-
tors) loci in CeD, but the molecular mech-
anism of action is still unknown [40, 41]. 
However, our co-expression network in-clud-
ed another member of this receptor family, 
NLRP7 (Figure 5). The exact link between 
NFE2L3 and the NOD2 pathway is unclear, 
but it is tempting to hypothesize on their 
potential relationship in the context of CeD.
Another interesting gene from the 
NFE2L3-co-expression network is C-X-C 
motif chemokine 10 (CXCL10), known 
also as IFNγ-induced protein 10 (IP-10). 
CXCL10 is secreted by several cell types 
(monocytes, macrophages, dendritic cells, 
endothelial cells and fibroblasts) in response 
to IFNγ or TNFα [42, 43]. This CXCL10 gene, 
its receptor CXCR3 and additional ligands 
of CXCR3 (CXCL9, CXCL11) are known as 
the most important chemokines promoting 
homing of immune cells into the inflamed 
tissue [44]. CXCR3, its ligands and their el-
evated levels in disease-relevant tissue from 
patients are known to be involved in dif-
ferent chronic inflammatory diseases, such 
as inflammatory bowel disease, rheumatoid ar-
thritis, type 1 diabetes, chronic autoim-mune 
thyroiditis, and others [45–53]. A recent 
study revealed high concentrations of CXCL10 
in the serum of untreated celiac patients, 
together with the highest mRNA levels of 
CXCL10 and CXCL11 being seen in duo-
denal biopsies from untreated CeD patients 
when compared to patients on a gluten-free 
diet (non-active celiac cases) or controls [54]. 
This suggests that this chemokine ligand-re-
ceptor interaction is involved in the inflam-
mation in active, untreated CeD. CXCR3 
and its ligands would seem to be potential 
biomarkers for the inflammation.
So far, the NFE2L3 gene/locus has only 
been potentially associated with two diseas-
es/phenotypes by GWAS: the genetic variant 
rs12700692 (which we have studied in CeD) 
was linked to endometriosis risk [55], and 
another variant, rs1055144,  was associated 
with waist-to-hip ratio, which is a measure-
ment of obesity and a common indicator for 
developing serious health conditions, in-
cluding diabetes [56]. This second variant 
is not in LD with our celiac SNP (r2=0.008). 
Both studies need further investigation in 
order to understand the potential involve-
ment of NFE2L3 in the disease mechanism.
We have presented an integrative ap-
proach to prioritize potentially functional 
genes for CeD by using genetic variants 
discovered by GWAS. Our results show that 
increasing the sample size to follow-up ge-
netic variants that are borderline-associated 
with disease can be useful in prioritizing 
novel risk genes. The same follow-up strat-
egy could also be used in other autoimmune 
and immune-related diseases. The next step 
could be to use genotyping platforms fo-
cused on known regions/genes arrays, as 
Immunochip [57] or MetaboChip [58], to 
fine map the region of interest and enrich 
it with lower frequency genetic variants, 
which are not covered by the standard ge-
nome-wide platforms and which represent 
an important bias in all GWAS. Our study 
also suggests that interesting candidate 
genes can be discovered within the group of 
variants that do not reach the genome-wide 
statistical threshold in GWAS, but display 
“suggestive” P-values, which might be im-
prove by increasing the sample size. This can 
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be done by increasing the number of cases 
with the same disease phenotype or, as pos-
sible for autoimmune and immune-related 
diseases, by merging different disease data-
sets and performing a meta-analysis to dis-
cover the shared genetic variants underlying 
the autoimmunity or shared disease mecha-
nisms and pathways.
In this follow-up study of GWAS results, 
we report two new loci associated with CeD, 
located in regions on chromosomes 1 and 7. 
We have identified NFE2L3 in the locus on 
chromosome 7 as a potential novel risk gene 
for CeD. Future studies will be needed to 
verify whether NFE2L3 is actually involved 
in the molecular mechanism of CeD and 
what its role is.
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rs12086216 0,581907909 1 FTLP17 104800294 ENSG00000228347 1 104696190 cis C/T T 0,550726348
rs12086216 0,599166157 1 RP11-97C18.1 104800294 ENSG00000225191 1 104469808 cis C/T T -0,525687678
rs12086216 0,764024605 1 RP11-364B6.1 104800294 ENSG00000215869 1 104617677 cis C/T T 0,300370647
rs12700692 1,16E-08 7 NFE2L3 26036724 ENSG00000050344 7 26209302 cis C/T T -5,705057269
rs12700692 0,220 7 CBX3 26036724 ENSG00000122565 7 26246879 cis C/T T -1,22720656
rs12700692 0,282 7 MIR148A 26036724 ENSG00000199085 7 25989572 cis C/T T -1,076787478
rs12700692 0,329 7 AC091705.1 26036724 ENSG00000227386 7 25589032 cis C/T T -0,976540998
rs12700692 0,354 7 CTA-242H14.1 26036724 ENSG00000239622 7 25729389 cis C/T T 0,926426721
rs12700692 0,395 7 AC004540.5 26036724 ENSG00000214870 7 26488403 cis C/T T 0,851265656
rs12700692 0,764 7 AC003090.1 26036724 ENSG00000223561 7 25711792 cis C/T T -0,300370647
rs12700692 0,822 7 AC004540.4 26036724 ENSG00000225792 7 26414042 cis C/T T 0,225274437
rs12700692 0,920 7 AC010677.5 26036724 ENSG00000232383 7 26316020 cis C/T T -0,100120345
rs12700692 0,940 7 HNRNPA2B1 26036724 ENSG00000122566 7 26235348 cis C/T T 0,075090127
rs12700692 0,940 7 SNX10 26036724 ENSG00000086300 7 26372745 cis C/T T 0,075090127
SNP, single nucleotide polymorphisms;  CHR, chromosome; HGNC Name, oficial gene name from HUGO Gene 
Nomenclature Committee; CHR Pos, chromosome  position;














































































































































lldeep_genelevel_TMM 0,550726348 629 -8,7547E-17 0,977376397 FTLP17 0,022145132 0.0 (0.0) 0.02214513181763136 (0.0399263595088662) 0
lldeep_genelevel_TMM -0,525687678 629 -8,95217E-18 0,048285454 RP11-97C18.1 -0,021277238 0.0 (0.0) -0.021277238388047313 (0.039927112203089754) 0
lldeep_genelevel_TMM 0,300370647 629 -1,12964E-16 0,198414236 RP11-364B6.1 0,012410487 0.0 (0.0) 0.012410487288996179 (0.03993307758606668) 0
lldeep_genelevel_TMM -5,705057269 629 -1,19936E-16 0,220741449 NFE2L3 -0,225492189 0.0 (0.0) -0.22549218866608242 (0.038907596599210864) 0
lldeep_genelevel_TMM -1,22720656 629 -5,84235E-17 0,077465537 CBX3 -0,048666078 0.0 (0.0) -0.04866607829187481 (0.03988883302026776) 0
lldeep_genelevel_TMM -1,076787478 629 -3,11478E-17 0,02259659 MIR148A -0,043170345 0.0 (0.0) -0.0431703450939714 (0.03989892175765398) 0
lldeep_genelevel_TMM -0,976540998 629 -8,27372E-18 0,073912141 AC091705.1 -0,038583326 0.0 (0.0) -0.03858332634487472 (0.039906416182325995) 0
lldeep_genelevel_TMM 0,926426721 629 -1,91421E-16 1,236962269 CTA-242H14.1 0,037205523 0.0 (0.0) 0.03720552281075252 (0.03990850279090622) 0
lldeep_genelevel_TMM 0,851265656 629 -5,61289E-17 2,785673431 AC004540.5 0,033655893 0.0 (0.0) 0.033655893408599175 (0.03991352855991889) 0
lldeep_genelevel_TMM -0,300370647 629 -7,34265E-17 3,280170478 AC003090.1 -0,012172179 0.0 (0.0) -0.012172179270946245 (0.03993319457282056) 0
lldeep_genelevel_TMM 0,225274437 629 2,80203E-16 2,636583519 AC004540.4 0,008642026 0.0 (0.0) 0.008642025888303874 (0.039934661855656105) 0
lldeep_genelevel_TMM -0,100120345 629 2,33374E-17 0,109121259 AC010677.5 -0,004459842 0.0 (0.0) -0.004459842006307055 (0.039935756020716834) 0
lldeep_genelevel_TMM 0,075090127 629 1,41205E-17 0,17034627 HNRNPA2B1 0,003286287 0.0 (0.0) 0.0032862869844921317 (0.03993593754208112) 0
lldeep_genelevel_TMM 0,075090127 629 7,75744E-17 0,105212313 SNX10 0,003001637 0.0 (0.0) 0.003001637468562597 (0.0399359732822129) 0
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Supplementary table 4.
Autoimmune and immune-related diseases















CXCL10                        







NFKBIE   Y  
SCN3A    




DNMT3L Y Y Y Y
IKBKE    
KLHL5    
ICAM1   Y Y Y Y Y Y Y Y




















EBF1   Y Y  


















































TMA16 = C4orf43    
BTN2A2 (MHC region) Y Y Y Y Y Y Y Y Y Y Y Y
BSPRY    
EPB41L2                        
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CSF2       Y               Y
ABCC1    






IL15RA   Y Y
NFKBIA   Y  
TNFRSF11A    




CTC-231O11.1 = MIR146A    
AFAP1    







































C9orf167 = TOR4A    
DNASE1L2    
CCR2     Y   Y           Y  
Disease abbreviations: AS ankylosing spondylitis; ATD autoimmune thyroid disease; CeD celiac disease; CD 
Crohn’s disease; JIA juvenile idiopathic arthritis; MS multiple sclerosis; PBC primary biliary cirrhosis; PS psoriasis; 
RA rheumatoid arthritis; SLE Systemic lupus erythematosus;  T1D Diabetes mellitus type 1; UC ulcerative colitis; 
Y= yes when gene is linked to the disease 

